General fitness, health and nutrition · Public discussion

New Pain Therapy

Started by Doe · · Last activity · 3 posts · 448 views

Thread details

What we know about this thread

Original section
General fitness, health and nutrition
Published
29 December 2003
Last activity
29 December 2003
Original author
Doe
Posts
3
Discussion status
Public discussion
Total views
448
Views / 30 days
0

The navigation and discussion metadata provide context. Posts remain in their original chronological order.

Showing posts 1–3 of 3
Posts remain in their original chronological order.

Text size
  1. tinyurl.com392oq

    New Pain Therapy Reverses Glial Activation

    By medinews.com staff writers Posted on 17 December 2003

    Researchers believe that delivering the gene for interleukin-10 (IL-10) to the affected region may
    reverse glial activation and relieve chronic pain. Their findings from a number of studies showing
    proof of principle were presented at the annual meeting of the Society of Neuroscience in New
    Orleans (LA, USA).

    Glial cells have an important role in pain. When they are activated in response to nerve damage,
    tumors, or viruses, they produce increased levels of substances that enhance the neuron’s response
    to pain signals. These substances then activate other glia. When a critical level is reached, it
    produces a self-perpetuating feedback loop that can continue even after the original cause of pain
    has been resolved. The researchers have focused on the effectiveness of the powerful, naturally
    occurring anti-inflammatory protein IL-10 to block or reverse glial activation. Studies in rats have
    demonstrated that it can prevent or reverse every enhanced pain state examined to date.

    “A new model for the etiology of chronic pain is quickly emerging as researchers around the world
    are developing a better understanding of the underlying causes of chronic pain,” said Linda
    Watkins, Ph.D., professor in the department of psychology and the Center for Neuroscience at the
    University of Colorado at Boulder (USA; www.colorado.edu) and co-author of a paper published in the
    December 1, 2003, issue of Nature Reviews Drug Discovery. Dr. Watkins and colleagues are working
    with Avigen, Inc. (San Francisco, CA, USA) on the development of a new pain treatment.

    Who loves ya. Tom Jesus Was A Vegetarian! jesuswasavegetarian.7h.comjesuswasavegetarian.7h.com Man Is A Herbivore!
    pages.ivillage.commanisaherbivore DEAD PEOPLE WALKING
    pages.ivillage.comdeadpeoplewalking

  2. Quoted message said:

    Subject: New Pain Therapy
    From: [email hidden] (doe)
    Date: 12/24/2003 1:27 PM Mountain Standard Time
    Message-id: <[email hidden]>

    tinyurl.com392oq

    New Pain Therapy Reverses Glial Activation

    By medinews.com staff writers Posted on 17 December 2003

    Researchers believe that delivering the gene for interleukin-10 (IL-10) to the affected region may
    reverse glial activation and relieve chronic pain. Their findings from a number of studies showing
    proof of principle were presented at the annual meeting of the Society of Neuroscience in New
    Orleans (LA, USA).

    Glial cells have an important role in pain. When they are activated in response to nerve damage,
    tumors, or viruses, they produce increased levels of substances that enhance the neuron’s
    response to pain signals. These substances then activate other glia. When a critical level is
    reached, it produces a self-perpetuating feedback loop that can continue even after the original
    cause of pain has been resolved. The researchers have focused on the effectiveness of the
    powerful, naturally occurring anti-inflammatory protein IL-10 to block or reverse glial
    activation. Studies in rats have demonstrated that it can prevent or reverse every enhanced pain
    state examined to date.

    “A new model for the etiology of chronic pain is quickly emerging as researchers around the world
    are developing a better understanding of the underlying causes of chronic pain,” said Linda
    Watkins, Ph.D., professor in the department of psychology and the Center for Neuroscience at the
    University of Colorado at Boulder (USA; www.colorado.edu) and co-author of a paper published in the
    December 1, 2003, issue of Nature Reviews Drug Discovery.
    Dr.Watkins and colleagues are working with Avigen, Inc. (San Francisco, CA, USA) on the development
    of a new pain treatment.

    Seems like it works DUE TO sequestering of .. iron.

    J Immunol. 2002 Aug 15;169(4):2204-9. Related Articles, Links

    Role of IL-10 for induction of anemia during inflammation.

    Tilg H, Ulmer H, Kaser A, Weiss G.

    Division of Gastroenterology and Hepatology, Department of Medicine, University Hospital Innsbruck,
    Innsbruck, Austria.

    Anemia is frequently observed in patients suffering from chronic inflammatory disorders. Recent in
    vitro data suggest that Th2 cytokines, such as IL-10, could be involved in its pathogenesis. We
    analyzed 1) changes in hemoglobin values in 329 patients with chronic active Crohn's disease
    receiving the anti-inflammatory cytokine IL-10 as part of a randomized, double-blind, placebo-
    controlled study, 2) serum iron parameters in a subgroup of these patients (n = 54), and 3) the in
    vitro effects of IL-10 on ferritin transcription and translation in human monocytic cells (THP-1) by
    means of Northern blot and immunoprecipitation after metabolic labeling. Patients receiving higher
    doses of IL-10 developed anemia and presented with a dose-dependent increase of ferritin and soluble
    transferrin receptor levels, an indicator of iron restriction to erythroid progenitor cells.
    According to our in vitro data, hyperferritinemia may result from direct stimulation of ferritin
    translation by IL-10 in activated monocytic cells, most likely by cytokine-mediated reduction of the
    binding affinity of translational repressors, iron-regulatory proteins, to the 5'-untranslated
    region of ferritin mRNA. In patients, all observed changes were most pronounced at the end of
    therapy (day +29), and thereafter hemoglobin levels and serum iron parameters returned to baseline
    levels within 4 wk of follow-up. Our data demonstrate that IL-10 causes anemia in patients with
    inflammatory bowel disease which may be referred to the induction of imbalances in iron homeostasis
    by the cytokine, leading to hyperferritinemia and limited iron availability to erythroid progenitor
    cells, a condition typically seen in the anemia of chronic inflammation.

    Publication Types: Clinical Trial Multicenter Study Randomized Controlled Trial

    PMID: 12165551 [PubMed - indexed for MEDLINE]

    --------------------------------------------------------------------------
    ------

    Who loves ya. Tom Jesus Was A Vegetarian! jesuswasavegetarian.7h.comjesuswasavegetarian.7h.com Man Is A Herbivore!
    pages.ivillage.commanisaherbivore DEAD PEOPLE WALKING
    pages.ivillage.comdeadpeoplewalking

  3. [email hidden] (doe) wrote in message
    :"]news:[email hidden]:

    Quoted message said:
    Quoted message said:

    Subject: New Pain Therapy From: [email hidden] (doe) Date: 12/24/2003 1:27 PM Mountain
    Standard Time Message-id: <[email hidden]>

    tinyurl.com392oq

    New Pain Therapy Reverses Glial Activation

    By medinews.com staff writers Posted on 17 December 2003

    Researchers believe that delivering the gene for interleukin-10 (IL-10) to the affected region may
    reverse glial activation and relieve chronic pain. Their findings from a number of studies showing
    proof of principle were presented at the annual meeting of the Society of Neuroscience in New
    Orleans (LA, USA).

    Glial cells have an important role in pain. When they are activated in response to nerve damage,
    tumors, or viruses, they produce increased levels of substances that enhance the neuron’s
    response to pain signals. These substances then activate other glia. When a critical level is
    reached, it produces a self-perpetuating feedback loop that can continue even after the original
    cause of pain has been resolved. The researchers have focused on the effectiveness of the
    powerful, naturally occurring anti-inflammatory protein IL-10 to block or reverse glial
    activation. Studies in rats have demonstrated that it can prevent or reverse every enhanced pain
    state examined to date.

    “A new model for the etiology of chronic pain is quickly emerging as researchers around the
    world are developing a better understanding of the underlying causes of chronic pain,” said
    Linda Watkins, Ph.D., professor in the department of psychology and the Center for Neuroscience at
    the University of Colorado at Boulder (USA; www.colorado.edu) and co-author of a paper published
    in the December 1, 2003, issue of Nature Reviews Drug Discovery. Dr. Watkins and colleagues are
    working with Avigen, Inc. (San Francisco, CA, USA) on the development of a new pain treatment.

    Seems like it works DUE TO sequestering of .. iron.

    Found your old fixation again?

    Quoted message said:

    J Immunol. 2002 Aug 15;169(4):2204-9. Related Articles, Links

    Role of IL-10 for induction of anemia during inflammation.

    Tilg H, Ulmer H, Kaser A, Weiss G.

    Division of Gastroenterology and Hepatology, Department of Medicine, University Hospital
    Innsbruck, Innsbruck, Austria.

    Anemia is frequently observed in patients suffering from chronic inflammatory disorders. Recent in
    vitro data suggest that Th2 cytokines, such as IL-10, could be involved in its pathogenesis. We
    analyzed 1) changes in hemoglobin values in 329 patients with chronic active Crohn's disease
    receiving the anti-inflammatory cytokine IL-10 as part of a randomized, double-blind, placebo-
    controlled study, 2) serum iron parameters in a subgroup of these patients (n = 54), and 3) the in
    vitro effects of IL-10 on ferritin transcription and translation in human monocytic cells (THP-1)
    by means of Northern blot and immunoprecipitation after metabolic labeling. Patients receiving
    higher doses of IL-10 developed anemia and presented with a dose-dependent increase of ferritin
    and soluble transferrin receptor levels, an indicator of iron restriction to erythroid progenitor
    cells. According to our in vitro data, hyperferritinemia may result from direct stimulation of
    ferritin translation by IL-10 in activated monocytic cells, most likely by cytokine-mediated
    reduction of the binding affinity of translational repressors, iron-regulatory proteins, to the
    5'-untranslated region of ferritin mRNA. In patients, all observed changes were most pronounced at
    the end of therapy (day +29), and thereafter hemoglobin levels and serum iron parameters returned
    to baseline levels within 4 wk of follow-up. Our data demonstrate that IL-10 causes anemia in
    patients with inflammatory bowel disease which may be referred to the induction of imbalances in
    iron homeostasis by the cytokine, leading to hyperferritinemia and limited iron availability to
    erythroid progenitor cells, a condition typically seen in the anemia of chronic inflammation.

    Publication Types: Clinical Trial Multicenter Study Randomized Controlled Trial

    PMID: 12165551 [PubMed - indexed for MEDLINE]

    -----------------------------------------------------------------------
    --- ------

    Who loves ya. Tom Jesus Was A Vegetarian! jesuswasavegetarian.7h.comjesuswasavegetarian.7h.com Man Is A Herbivore!
    pages.ivillage.commanisaherbivore DEAD PEOPLE WALKING
    pages.ivillage.comdeadpeoplewalking

Active in the last 60 minutes

Active in this thread

0 users · 0 guests ·0 bots ·0 total

No signed-in users are active right now.

No known search crawlers active right now.